Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 3, pp 477–485

Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center

Original Paper



To explore the risk factors and treatment outcomes of contralateral new upper tract urothelial carcinoma (UTUC) after nephroureterectomy in a large single-center cohort of UTUC patients.


A retrospective analysis of the clinicopathological data of 509 consecutive patients treated by nephroureterectomy from 2000 to 2010 at a high-volume center in China was conducted.


Thirty-five patients (6.9 %) were found to develop contralateral UTUC. Gross hematuria was a common symptom, and aristolochic acid (AA) containing Chinese herbs was identified as an underlying cause. In multivariate analysis, renal transplant recipients (HR = 16.507) and preoperative renal insufficiency (HR = 2.523) were independent risk factors. No correlation was found in the clinical and pathological characteristics of primary and subsequent contralateral UTUC. A second round of nephroureterectomy should be performed on renal transplant patients, whereas patients who are older, exhibit relatively better renal function, and have tumors that are single, located in the ureter and small size could be treated with nephron-sparing surgery. No survival difference was detected between the two treatment groups, and developing contralateral UTUC was not associated with worse survival.


Contralateral UTUC is comparatively rare, and gross hematuria is a common symptom. Renal transplant history and renal insufficiency are independent risk factors, and prophylactic contralateral nephroureterectomy is considered for uremic UTUC patients with proper renal replacement treatment or renal transplant recipients. These features are likely related to the mechanisms of multifocality of UTUC, and the potential correlation with AA remains to be elucidated. Tumor characteristics and renal function are informative for the decisions concerning surgical options for contralateral UTUC.


Upper tract urothelial carcinoma (UTUC) Radical nephroureterectomy (RNU) Contralateral Chronic kidney disease (CKD) Renal transplant Prognosis 


  1. Bloom NA, Vidone RA, Lytton B (1970) Primary carcinoma of the ureter: a report of 102 new cases. J Urol 103(5):590–598PubMedGoogle Scholar
  2. Charbit L, Gendreau MC, Mee S, Cukier J (1991) Tumors of the upper urinary tract: 10 years of experience. J Urol 146(5):1243–1246PubMedGoogle Scholar
  3. Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS (2013) Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer 133(1):14–20PubMedCrossRefGoogle Scholar
  4. Colin P, Ouzzane A, Pignot G, Ravier E, Crouzet S, Ariane MM, Audouin M, Neuzillet Y, Albouy B, Hurel S, Saint F, Guillotreau J, Guy L, Bigot P, De La Taille A, Arroua F, Marchand C, Matte A, Fais PO, Roupret M (2012) Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 110(8):1134–1141PubMedCrossRefGoogle Scholar
  5. Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C (1999) Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 33(6):1011–1017PubMedCrossRefGoogle Scholar
  6. Cummings KB (1980) Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin N Am 7(3):569–578Google Scholar
  7. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS Jr (2010) Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 183(6):2148–2153PubMedCrossRefGoogle Scholar
  8. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O (1993) Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342(8879):1087–1088PubMedCrossRefGoogle Scholar
  9. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J, Hofstaedter F, Hartmann A (2001) Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20(35):4910–4915PubMedCrossRefGoogle Scholar
  10. Holmang S, Johansson SL (2006) Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol 175(1):69–72 (discussion 72–63)PubMedCrossRefGoogle Scholar
  11. Hou HJ, Xiao J, Tian Y (2013) Contralateral nephroureterectomy for renal transplant recipients with unilateral upper urinary tract transitional cell carcinoma: a report of 12 cases. Transplant Proc 45(6):2203–2206PubMedCrossRefGoogle Scholar
  12. Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, Shiue YL (2003) The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 98(8):1620–1626PubMedCrossRefGoogle Scholar
  13. Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, Chang SJ, Shen JT, Chou YH, Huang CH (2008a) Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 54(5):1127–1134PubMedCrossRefGoogle Scholar
  14. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD (2008b) Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol 15(1):53–57PubMedCrossRefGoogle Scholar
  15. Li HZ, Xia M, Han Y, Xu XG, Zhang YS (2009) De novo urothelial carcinoma in kidney transplantation patients with end-stage aristolochic acid nephropathy in China. Urol Int 83(2):200–205PubMedCrossRefGoogle Scholar
  16. Li WM, Shen JT, Li CC, Ke HL, Wei YC, Wu WJ, Chou YH, Huang CH (2010) Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 57(6):963–969PubMedCrossRefGoogle Scholar
  17. Liao CH, Chueh SC, Lai MK, Chen J (2004) Transitional cell carcinoma in renal transplant recipients. Transplant Proc 36(7):2152–2153PubMedCrossRefGoogle Scholar
  18. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17(10):2937–2944PubMedCrossRefGoogle Scholar
  19. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J (2000) Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 164(4):1183–1187PubMedCrossRefGoogle Scholar
  20. Miyake H, Hara I, Kamidono S, Eto H (2004) Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 172(3):1127–1129PubMedCrossRefGoogle Scholar
  21. Mufti GR, Gove JR, Badenoch DF, Fowler CG, Tiptaft RC, England HR, Paris AM, Singh M, Hall MH, Blandy JP (1989) Transitional cell carcinoma of the renal pelvis and ureter. Br J Urol 63(2):135–140PubMedCrossRefGoogle Scholar
  22. Nakazawa R, Miyano S, Sasaki H, Kudo H, Kimura K, Chikaraishi T (2011) Synchronous bilateral urothelial cancer in a kidney recipient. Int J Urol 18(12):847–850PubMedCrossRefGoogle Scholar
  23. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342(23):1686–1692PubMedCrossRefGoogle Scholar
  24. Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, Martignoni G, Patard JJ, Artibani W, Ficarra V (2009) Independent predictors of contralateral metachronous upper urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from three European centers. Int J Urol 16(2):187–191PubMedCrossRefGoogle Scholar
  25. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059–1071PubMedCrossRefGoogle Scholar
  26. Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR (2009) The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant 24(10):3225–3231PubMedCrossRefGoogle Scholar
  27. Wu MJ, Lian JD, Yang CR, Cheng CH, Chen CH, Lee WC, Shu KH, Tang MJ (2004) High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 43(6):1091–1097PubMedCrossRefGoogle Scholar
  28. Wu CF, Chang PL, Chen CS, Chuang CK, Weng HH, Pang ST (2006) The outcome of patients on dialysis with upper urinary tract transitional cell carcinoma. J Urol 176(2):477–481PubMedCrossRefGoogle Scholar
  29. Xiong G, Chen X, Li X, Fang D, Zhang L, Yang L, Zhang L, Yao L, He Z, Zhou L (2013) Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. doi: 10.1016/j.jfma.2013.04.001. [Epub ahead of print]

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Dong Fang
    • 1
  • Lei Zhang
    • 1
  • Xuesong Li
    • 1
  • Gengyan Xiong
    • 1
  • Xiaopeng Chen
    • 1
    • 2
  • Wenke Han
    • 1
  • Zhisong He
    • 1
  • Liqun Zhou
    • 1
  1. 1.Department of Urology, Peking University First Hospital, Institute of UrologyPeking University, National Urological Cancer CentreBeijingChina
  2. 2.Department of Urology, Tangdu HospitalFourth Military Medical UniversityXi’anChina

Personalised recommendations